OR WAIT null SECS
Under the agreement, gene and cell therapy companies can go directly to Aldevron for NTC’s technology without acquiring a license from NTC.
Aldevron, a biotechnology company based in Fargo, ND, announced the availability of Nanoplasmids and antibiotic-free RNA-OUT technology for use in gene therapy manufacturing through a license agreement with Nature Technology Corporation (NTC), a biotechnology company in Lincoln, NE, that provides its industry partners with non-viral vectors and processes for gene therapy.
Under the agreement, gene and cell therapy companies can go directly to Aldevron for NTC’s technology without acquiring a license from NTC, according to an Oct. 22, 2019 press release. Additionally, when the NTC plasmid is not the active pharmaceutical ingredient or in the final product, companies do not need to pay royalties or license fees other than the purchase price of the product.
“Gene and cell therapy researchers continue to make incredible discoveries that will improve lives for millions of people,” said Michael Chambers, Aldevron CEO, in the press release. “Aldevron is committed to providing the best manufacturing technologies to support their breakthrough treatments. Our partnership with NTC enables us to provide plasmid technology that significantly improves the manufacturing process and reduces regulatory risk, resulting in reduced costs and faster time to patients.”
“Our Nanoplasmid and RNA-OUT technology has been under development for 12 years and can provide demonstrable advantages for viral vector manufacturing,” added Clague Hodgson, CEO of NTC, in the press release. “We are pleased to collaborate with Aldevron to make this technology immediately available to its clients so they can avoid the delay and expense associated with the licensing process thereby reducing the barriers to delivering transformative treatments to patients.”